EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating FavorableSafety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide
Combination of ruvonoflast and semaglutide produced greater reductions in hsCRP versussemaglutide monotherapy Boston, MA, October 7, 2026 – Rezera Inc. (the “Company”), a
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
· Epidarex Capital Fund IV participates in Series A alongside BioGeneration Ventures, Angelini Ventures, Kurma Partners, Vesalius Biocapital Partners, ROM-Utrecht Region, p53 Invest